Jorge Garcia, PharmD, MS, MHA, MBA, FACHE, Baptist Health South Florida, spoke about his panel held at the recent Institute for Value-Based Medicine® that The American Journal of Managed Care® cohosted with Providence Health System.
Jorge Garcia, PharmD, MS, MHA, MBA, FACHE, assistant vice president of system oncology and infusion pharmacy services, Baptist Health South Florida, spoke about his panel on ambulatory drug infusion that was featured at the recent Institute for Value-Based Medicine (IVBM) held in Newport Beach, California, cohosted by The American Journal of Managed Care and Providence Health System.
Transcript
What were you most looking forward to at the IVBM conference in Newport Beach?
I think what I'm most excited about is just coming together with colleagues to understand how they're working through different challenges and opportunities in their respective facilities and what I can bring back to my home institution to continue to advance health care.
What can attendees expect from your presentation on ambulatory drug infusion?
Over the years, I have sometimes gotten phone calls about patients who need nononcology infusion therapy. Sometimes the providers will call directly and they would ask me, "Help me find a share to infuse this patient, otherwise I may need to bring the patient through the Emergency Department. Or even worse, I may need to get the patient admitted."
As we know, that's not ideal, using those acute health care resources for an infusion that could otherwise be provided to the patient in the ambulatory setting. So with that vision in mind, we have put in practice a new service line that looks at ambulatory infusions for patients. Now we've operated the centers for 3 years, and we've learned a lot along the way; we've definitely opened access. We would love to share our experiences, our successes, and the challenges that we continue to work through to ensure that there is good access to nononcology infusion medicines in our community.
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More